Skip to main content
. 2016 Mar;13(3):342–349. doi: 10.1513/AnnalsATS.201509-631OC

Table 1.

Baseline characteristics of the Multicenter International Lymphangioleiomyomatosis Efficacy and Safety of Sirolimus computed tomography cohort

Variable Placebo (n = 14) Sirolimus (n = 17) P Value
Age, yr
43 (35–55) 44 (42–57) 0.31
Race White, n 8 10 1.00
Asian, n 6 7
FEV1 Volume, L 1.44 (0.96–1.68) 1.18 (1.05–1.46) 0.32
Percentage of predicted value 52 (35–60) 44 (42–50) 0.62
FVC Volume, L 3.19 (2.20–3.54) 2.53 (2.03–2.85) 0.15
Percentage of predicted value 84 (77–99) 75 (66–82) 0.15
FEV1/ FVC
0.44 (0.38–0.58) 0.48 (0.41–0.54) 0.65
TLC Volume, L 5.68 (4.75–6.48) 5.15 (4.59–5.57) 0.13
Percentage of predicted value 114 (104–130) 102 (97–131) 0.19
FRC, n = 30 Volume, L 3.33 (2.43–3.60) 2.98 (2.27–3.17) 0.22
Percentage of predicted value 117 (112–129) 109 (101–117) 0.18
RV Volume, L 2.45 (1.84–2.86) 2.36 (2.13–2.79) 0.86
Percentage of predicted value 149 (113–209) 149 (113–188) 0.92
DlCO, n = 30 ml/min/mm Hg 12.0 (6.96–14.0) 8.93 (8.30–11.95) 0.65
Percentage of predicted value 46.7 (33.0–62.6) 43.2 (37.6–49.5) 0.65
Expiratory cyst volume, %   13.89 16.35 0.45

Definition of abbreviations: DlCO = diffusing capacity of carbon monoxide; RV = residual volume; TLC = total lung capacity.

The median values for the age and pulmonary function test variable values are presented. The lower and upper quartiles are represented in parentheses.